[go: up one dir, main page]

IN2013MU00711A - - Google Patents

Download PDF

Info

Publication number
IN2013MU00711A
IN2013MU00711A IN711MU2013A IN2013MU00711A IN 2013MU00711 A IN2013MU00711 A IN 2013MU00711A IN 711MU2013 A IN711MU2013 A IN 711MU2013A IN 2013MU00711 A IN2013MU00711 A IN 2013MU00711A
Authority
IN
India
Prior art keywords
disclosed
fidaxomicin
optionally
useful
preparation
Prior art date
Application number
Inventor
Geena Malhotra
Shrinivas Madhukar Purandare
Original Assignee
Cipla Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cipla Ltd filed Critical Cipla Ltd
Priority to EP14712706.2A priority Critical patent/EP2964196A1/en
Priority to RU2015140498A priority patent/RU2015140498A/en
Priority to ZA2014/01683A priority patent/ZA201401683B/en
Priority to MX2015011894A priority patent/MX2015011894A/en
Priority to CA2902852A priority patent/CA2902852A1/en
Priority to JP2015560777A priority patent/JP2016511268A/en
Priority to US14/770,315 priority patent/US20160002278A1/en
Priority to CN201480012934.5A priority patent/CN105142612A/en
Priority to BR112015021501A priority patent/BR112015021501A2/en
Priority to PCT/GB2014/050678 priority patent/WO2014135891A1/en
Priority to IN711MU2013 priority patent/IN2013MU00711A/en
Priority to AU2014224397A priority patent/AU2014224397A1/en
Publication of IN2013MU00711A publication Critical patent/IN2013MU00711A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/122—Foams; Dry foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/124—Aerosols; Foams characterised by the propellant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

Disclosed herein is a pharmaceutical composition for rectal administration comprising fidaxomicin optionally with one or more pharmaceutically acceptable excipients, useful in the treatment of infections caused by Clostridium difficile and also disclosed herein a process for preparation thereof.
IN711MU2013 2013-03-08 2014-03-07 IN2013MU00711A (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
EP14712706.2A EP2964196A1 (en) 2013-03-08 2014-03-07 Pharmaceutical compositions for rectal administration
RU2015140498A RU2015140498A (en) 2013-03-08 2014-03-07 Pharmaceutical compositions for rectal administration
ZA2014/01683A ZA201401683B (en) 2013-03-08 2014-03-07 Pharmaceutical compositions for rectal administration
MX2015011894A MX2015011894A (en) 2013-03-08 2014-03-07 Pharmaceutical compositions for rectal administration.
CA2902852A CA2902852A1 (en) 2013-03-08 2014-03-07 Pharmaceutical compositions for rectal administration
JP2015560777A JP2016511268A (en) 2013-03-08 2014-03-07 Pharmaceutical composition for rectal administration
US14/770,315 US20160002278A1 (en) 2013-03-08 2014-03-07 Pharmaceutical Compositions for Rectal Administration
CN201480012934.5A CN105142612A (en) 2013-03-08 2014-03-07 Pharmaceutical compositions for rectal administration
BR112015021501A BR112015021501A2 (en) 2013-03-08 2014-03-07 pharmaceutical composition, foamable pharmaceutical composition, process for manufacturing a pharmaceutical composition for rectal administration, aerosol can for a pharmaceutical composition, use of a pharmaceutical composition and method for treating or maintaining remission of infections caused by clostridium difficile
PCT/GB2014/050678 WO2014135891A1 (en) 2013-03-08 2014-03-07 Pharmaceutical compositions for rectal administration
IN711MU2013 IN2013MU00711A (en) 2013-03-08 2014-03-07
AU2014224397A AU2014224397A1 (en) 2013-03-08 2014-03-07 Pharmaceutical compositions for rectal administration

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN711MU2013 IN2013MU00711A (en) 2013-03-08 2014-03-07

Publications (1)

Publication Number Publication Date
IN2013MU00711A true IN2013MU00711A (en) 2015-06-26

Family

ID=50382472

Family Applications (1)

Application Number Title Priority Date Filing Date
IN711MU2013 IN2013MU00711A (en) 2013-03-08 2014-03-07

Country Status (12)

Country Link
US (1) US20160002278A1 (en)
EP (1) EP2964196A1 (en)
JP (1) JP2016511268A (en)
CN (1) CN105142612A (en)
AU (1) AU2014224397A1 (en)
BR (1) BR112015021501A2 (en)
CA (1) CA2902852A1 (en)
IN (1) IN2013MU00711A (en)
MX (1) MX2015011894A (en)
RU (1) RU2015140498A (en)
WO (1) WO2014135891A1 (en)
ZA (1) ZA201401683B (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104546672B (en) * 2014-12-19 2017-12-22 华北制药集团新药研究开发有限责任公司 A kind of feldamycin enteric coated preparations
GB201509326D0 (en) 2015-05-29 2015-07-15 Antibio Tx Aps Novel use
RU2646495C2 (en) * 2015-12-28 2018-03-05 Общество с ограниченной ответственностью "Научно-техническая производственная фирма "Анта-Медикал" Pharmaceutical compositions as rectal suppositories containing nefopam hydrochloride (versions), their application for treatment of acute and chronic pain syndrome and methods for production
WO2018009789A1 (en) * 2016-07-08 2018-01-11 Vanderbilt University Treatment and prevention of clostridium difficile colitis using misoprostol
RU2661618C1 (en) * 2017-11-23 2018-07-17 Общество с ограниченной ответственностью "Научно-техническая производственная фирма "Анта-Медикал" Nephopam suppositories for the treatment of acute and chronic pain syndrome on a lipophilic basis and the method for their preparation
RU2661617C1 (en) * 2017-11-23 2018-07-17 Общество с ограниченной ответственностью "Научно-техническая производственная фирма "Анта-Медикал" Nephopam suppositories for the treatment of acute and chronic pain syndrome on a hydrophilic emulsion based and method for their preparation
JP2021524505A (en) * 2018-05-19 2021-09-13 ゲイリー ビンヤミン， Foam preparation and delivery method to the body
CN109394694A (en) * 2018-09-30 2019-03-01 北京兴源联合医药科技有限公司 A kind of water-free foam agent
CN112791048B (en) * 2020-12-31 2023-01-17 海南海神同洲制药有限公司 Sertaconazole nitrate suppository and preparation method thereof
CA3216267A1 (en) * 2021-04-22 2022-10-27 Glenn W. Laub Foam compositions for treating clostridioides difficile infections

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1458512A (en) 1973-11-22 1976-12-15 Lepetit Spa Antibiotic substance
US5767096A (en) * 1996-07-12 1998-06-16 Abbott Laboratories Bromotiacumicin compounds
US6969520B2 (en) 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
IL152486A0 (en) * 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
US9211259B2 (en) * 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US20070292461A1 (en) * 2003-08-04 2007-12-20 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US20080206161A1 (en) * 2002-10-25 2008-08-28 Dov Tamarkin Quiescent foamable compositions, steroids, kits and uses thereof
US20070292355A1 (en) * 2002-10-25 2007-12-20 Foamix Ltd. Anti-infection augmentation foamable compositions and kit and uses thereof
US8486374B2 (en) * 2003-08-04 2013-07-16 Foamix Ltd. Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
BRPI0412975A (en) * 2003-08-25 2006-10-03 Foamix Ltd penetrating foam for pharmaceutical use
US7906489B2 (en) 2004-05-14 2011-03-15 Optimer Pharmaceuticals, Inc. 18-membered macrocycles and analogs thereof
US7378508B2 (en) 2007-01-22 2008-05-27 Optimer Pharmaceuticals, Inc. Polymorphic crystalline forms of tiacumicin B
US20080292560A1 (en) * 2007-01-12 2008-11-27 Dov Tamarkin Silicone in glycol pharmaceutical and cosmetic compositions with accommodating agent
GB0921288D0 (en) 2009-12-04 2010-01-20 Health Prot Agency Therapies for preventing or suppressing clostridium difficile infection
AU2011255630B2 (en) * 2010-05-18 2015-04-30 Merck Sharp & Dohme Llc Treatment of Clostridium difficile infection in patients undergoing antibiotic therapy
US20130022575A1 (en) 2011-07-19 2013-01-24 Microbial Rx Systems and methods of replacing intestinal flora

Also Published As

Publication number Publication date
CN105142612A (en) 2015-12-09
US20160002278A1 (en) 2016-01-07
MX2015011894A (en) 2015-12-15
WO2014135891A1 (en) 2014-09-12
CA2902852A1 (en) 2014-09-12
RU2015140498A (en) 2017-04-13
BR112015021501A2 (en) 2017-07-18
AU2014224397A1 (en) 2015-09-10
JP2016511268A (en) 2016-04-14
EP2964196A1 (en) 2016-01-13
ZA201401683B (en) 2017-06-28

Similar Documents

Publication Publication Date Title
IN2013MU00711A (en)
NZ734233A (en) Pharmaceutical compositions comprising meloxicam
IN2013MU03583A (en)
NZ728072A (en) Modulators of toll-like receptors for the treatment of hiv
MX2015016983A (en) Nuclear transport modulators and uses thereof.
NZ760790A (en) Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 inhibitor and uses thereof
MX2021011906A (en) Delayed release compositions of linaclotide.
MX360650B (en) COMPOUNDS and METHODS FOR TREATING BACTERIAL INFECTIONS.
PH12016500465B1 (en) Deoxynojirimycin derivatives and methods of their using
PH12016502243A1 (en) Pharmaceutical compositions for treating infectious diseases
MX2022006770A (en) Bendamustine solid dispersions and continuous infusion.
IN2013MU01985A (en)
WO2014122460A3 (en) Pemetrexed complexes and pharmaceutical compositions containing pemetrexed complexes
IN2013MU01111A (en)
MX370957B (en) Compound of the avermectin family or of the milbemycin family for the treatment and/or prevention of atopic dermatitis.
IN2013MU03370A (en)
IN2013CH04314A (en)
IN2013MU01226A (en)
IN2013MU02015A (en)
TN2014000484A1 (en) Dronedarone for use in leishmaniasis, formulations and associations for use in leishmaniasis.
MX2016010104A (en) Use of paricalcitol in the treatment of inflammatory anaemia.
MX2016002186A (en) Process for preparing dronedarone and salts thereof.
UA89330U (en) Method for preventing inflammatory syndrome of immunity restoration in hiv-infected patients with cerebral toxoplasmosis
IN2013MU01160A (en)
IN2013CH03945A (en)